175 completed. 175 Phase 1, 59 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 175 | Completed 175 |
| Phase 2 | 59 | Completed 59 |
Follow Fibrosis: new trials by email Literature Review of Fibrosis trials Research Report on Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects HRS-9813 Capsule, Nintedanib Soft Capsules, Pirfenidone Tablets - Pulmonary Fibrosis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 20 | 2026-04-04 | 2026-09-21 |
| Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls Hydronidone capsules - Liver Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 30 | 2026-03-25 | 2026-08-13 |
| QTc Assessment in a Single-Dose Study of Hydronidone Capsules Hydronidone, Placebo - Hepatic Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 48 | 2025-12-30 | 2026-08-13 |
| The Phase Ⅰd Clinical Trial of Hydronidone Capsules Hydronidone capsules, Placebo capsules - Liver Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 138 | 2025-12-24 | 2026-09-21 |
| Bioequivalence and Adhesion of a Rotigotine Patch in Healthy Subjects Rotigotine Transdermal Delivery System (TDS) - Bioequivalence, Adhesion | Phase 1 | Completed | Amarin Technologies S.A.U. | 35 | 2025-12-04 | 2026-08-19 |
| The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. AZD2389, PET scan and radioligand - Liver Fibrosis, Hepatic Cirrhosis | Phase 1 | Completed | AstraZeneca | 8 | 2025-05-26 | 2026-07-27 |
| A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine AZD2389, Quinidine - Advanced Chronic Liver Disease, Healthy Participants | Phase 1 | Completed | AstraZeneca | 16 | 2025-05-12 | 2025-07-25 |
| A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants AZD2389, Midazolam, Caffeine - Advanced Chronic Liver Disease, Healthy Participants | Phase 1 | Completed | AstraZeneca | 16 | 2025-05-08 | 2025-07-24 |
| A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects HRS-9813 Capsule, HRS-9813 Tablet - Pulmonary Fibrosis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 12 | 2025-05-04 | 2025-07-08 |
| A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury CS0159 - Primary Biliary Cholangitis | Phase 1 | Completed | Cascade Pharmaceuticals, Inc | 24 | 2025-03-13 | 2025-07-11 |
| A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 AZD2389 - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 35 | 2025-02-04 | 2025-09-24 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure CHF10073 (Part 1 - SAD), Placebo (Part 1 - SAD), CHF10073 (Part 2 - MAD) - Pulmonary Fibrosis | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 155 | 2025-01-13 | 2026-02-12 |
| Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib Nintedanib 150 MG [Ofev] - Drug Interactions | Phase 1 | Completed | PureTech | 24 | 2024-12-17 | 2026-08-13 |
| A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants Zibotentan - Liver Cirrhosis | Phase 1 | Completed | AstraZeneca | 30 | 2024-12-05 | 2025-12-04 |
| Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC) PVT201, Placebo - Primary Biliary Cholangitis (PBC) | Phase 1 | Completed | Parvus Therapeutics, Inc. | 24 | 2024-10-15 | 2025-11-24 |
| A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. K-808 - Primary Biliary Cholangitis, Compensated Cirrhosis | Phase 1 | Completed | Kowa Research Institute, Inc. | 17 | 2024-10-01 | 2025-05-23 |
| Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment Mesenchymal Stem Cells from Wharton´s jelly - Systemic Sclerosis Pulmonary, Pulmonary Hypertension | Phase 1 / Phase 2 | Completed | Fundación Neumologica Colombiana | 1 | 2024-05-15 | 2026-04-21 |
| Study of [14C]CS0159 in China Healthy Subjects [14C]CS0159 - Primary Biliary Cholangitis | Phase 1 | Completed | Cascade Pharmaceuticals, Inc | 6 | 2023-10-23 | 2023-11-21 |
| A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants BMS-986278, Drospirenone/Ethinyl Estradiol - Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 37 | 2023-08-18 | 2024-01-24 |
| Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease Dasatinib 100 MG + Quercetin (1000 MG), Placebo - NAFLD, NASH With Fibrosis | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 30 | 2023-07-05 | 2026-04-15 |
Showing 20 of 175. Sign in to see all of them.
Liver Cirrhosis (49) · Cicatrix (29) · Pulmonary Fibrosis (20) · Liver Cirrhosis, Biliary (19) · Keloid (11) · Non-alcoholic Fatty Liver Disease (11) · Tissue Adhesions (10) · Idiopathic Pulmonary Fibrosis (9) · Carcinoma, Hepatocellular (6) · Hepatitis C (6) · Cicatrix, Hypertrophic (5) · Lung Diseases (5) · Neoplasms (5) · Hepatic Encephalopathy (4)
Pathological Conditions, Signs and Symptoms (175) · Pathologic Processes (174) · Digestive System Diseases (96) · Liver Diseases (86) · Lung Diseases, Interstitial (21) · Bile Duct Diseases (20) · Biliary Tract Diseases (20) · Respiratory Tract Diseases (20) · Cholestasis, Intrahepatic (19) · Cicatrix (19) · Lung Diseases (18) · Cholestasis (17) · Liver Cirrhosis (17) · Skin and Connective Tissue Diseases (16)
TGFB3 protein, human (9) · NRL972 (5) · ICG 001 (4) · Rituximab (3) · Saline Solution (3) · Sodium Chloride (3) · hydronidone (3) · pirfenidone (3) · Ltbp3 protein, zebrafish (2) · Pegbelfermin (2) · Sorafenib (2) · Transforming Growth Factor beta3 (2) · nintedanib (2) · (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid (1) · 130-nm albumin-bound paclitaxel (1)
Renovo (10) · AstraZeneca (5) · Bristol-Myers Squibb (5) · Norgine (5) · GlaxoSmithKline (4) · Beijing Continent Pharmaceutical Co, Ltd. (3) · Cascade Pharmaceuticals, Inc (3) · Kiminori Kimura, MD (3) · Mayo Clinic (3) · Royan Institute (3) · AiViva BioPharma, Inc. (2) · Albireo (2) · Gilead Sciences (2) · Guangdong Hengrui Pharmaceutical Co., Ltd (2) · Guangzhou JOYO Pharma Co., Ltd (2)
United States (70) · United Kingdom (19) · China (18) · Germany (9) · Australia (7) · Italy (6) · Japan (6) · Canada (5) · Belgium (4) · Iran (4) · South Korea (4) · Spain (4) · Bulgaria (3) · Hungary (3) · Denmark (2)
Jonathan Duncan (4) · Kiminori Kimura, MD (4) · Michael J Davies (3) · Hamid Gourabi, PhD (2) · Hossein Baharvand, PhD (2) · Jasmohan S Bajaj, MD, MSc (2) · Jeremy Bond (2) · Zahariy Krastev, MD (2) · Adam C Yopp, MD (1)
PMID 19362676, PMID 10655252, PMID 17694216, PMID 17903050, PMID 18068515, PMID 18346996, PMID 18459515, PMID 19146602, PMID 21194255, PMID 21233083, PMID 21751289, PMID 22282526, PMID 23077622, PMID 23220074, PMID 23453404, PMID 23565181, PMID 23590233, PMID 24074360, PMID 25485805, PMID 25667206, PMID 25906706, PMID 26336510, PMID 26869678, PMID 26972567, PMID 27148676, PMID 27192671, PMID 27484782, PMID 27741170, PMID 28249726, PMID 28284916, PMID 28653751, PMID 28844410, PMID 30416313, PMID 31038755, PMID 31429027, PMID 31632000, PMID 31751317, PMID 33463535, PMID 34282496, PMID 35605429, PMID 35667792, PMID 36442892, PMID 36914828, PMID 37278638, PMID 37374884, PMID 38015039, PMID 38153225, PMID 38344178, PMID 38677720, PMID 39115183
2016 (2), 2018 (2), N01CN00042 (1), P01CA108671 (1), P30CA015083 (1), R03DK052344 (1), R21DK111217 (1), R21TR002024 (1), U01AT004428 (1), UM1CA186686 (1)